Cash Flow Statement

Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Zentalis Pharmaceuticals (ZNTL) Deferred Taxes (2022 - 2023)

Zentalis Pharmaceuticals has reported Deferred Taxes over the past 2 years, most recently at -$756000.0 for Q2 2023.

For Q2 2023, Deferred Taxes fell 1121.62% year-over-year to -$756000.0; the TTM value through Mar 2024 reached -$756000.0, up 4.55%, while the annual FY2023 figure was -$853000.0, 10.92% down from the prior year.
Deferred Taxes for Q2 2023 was -$756000.0 at Zentalis Pharmaceuticals, down from -$97000.0 in the prior quarter.
Over five years, Deferred Taxes peaked at $74000.0 in Q2 2022 and troughed at -$769000.0 in Q4 2022.